Genenta Science S.p.A. (GNTA) 10-Year Financial Performance & Capital Metrics

GNTA • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutGenenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.Show more

Revenue $0
EBITDA -$10M +16.9%
Net Income -$9M +23.5%
EPS (Diluted) -0.49 +23.4%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -54.13% -19.9%
ROIC -59.37% +39.0%
Debt/Equity 0.00
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 4 (bottom 4%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-46.32%

EPS CAGR

10Y-

5Y-

3Y-

TTM-35.14%

ROCE

10Y Avg-35.62%

5Y Avg-37.84%

3Y Avg-45.1%

Latest-58.58%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-
Cost of Goods Sold+	0	1.77K	5.08K	6.03K	41.58K	0
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	0	-1.77K	-5.08K	-6.03K	-41.58K	0
Gross Margin %	-	-	-	-	-	-
Gross Profit Growth %	-	-	-1.87%	-0.19%	-5.9%	1%
Operating Expenses+	4.62M	5.59M	5.69M	11.04M	11.73M	9.76M
OpEx % of Revenue	-	-	-	-	-	-
Selling, General & Admin	921.52K	901.76K	2.3M	5.71M	5.26M	4.95M
SG&A % of Revenue	-	-	-	-	-	-
Research & Development	3.7M	4.69M	3.39M	5.34M	6.47M	4.81M
R&D % of Revenue	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0
Operating Income+	-4.62M	-5.59M	-5.69M	-11.04M	-11.73M	-9.76M
Operating Margin %	-	-	-	-	-	-
Operating Income Growth %	-	-0.21%	-0.02%	-0.94%	-0.06%	0.17%
EBITDA+	0	-5.59M	-5.68M	-11.04M	-11.69M	-9.72M
EBITDA Margin %	-	-	-	-	-	-
EBITDA Growth %	-	-	-0.02%	-0.94%	-0.06%	0.17%
D&A (Non-Cash Add-back)	4.62M	1.77K	5.08K	6.03K	42.45K	44.52K
EBIT	-4.62M	-5.59M	-5.69M	-11.04M	-11.73M	-9.76M
Net Interest Income+	-9.54K	-7.75K	-11.7K	36.98K	0	81.14K
Interest Income	10	8	12	37	0	81.14K
Interest Expense	9.55K	7.75K	11.72K	0	0	0
Other Income/Expense	26.78K	-1.79K	157.94K	2.57M	87.49K	851.82K
Pretax Income+	-4.6M	-5.59M	-5.53M	-8.48M	-11.65M	-8.91M
Pretax Margin %	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%
Net Income+	-4.61M	-5.61M	-5.53M	-8.48M	-11.65M	-8.91M
Net Margin %	-	-	-	-	-	-
Net Income Growth %	-	-0.22%	0.01%	-0.53%	-0.37%	0.23%
Net Income (Continuing)	-4.6M	-5.59M	-5.53M	-8.48M	-11.65M	-8.91M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.25	-0.31	-0.31	-0.47	-0.64	-0.49
EPS Growth %	-	-0.24%	0%	-0.52%	-0.36%	0.23%
EPS (Basic)	-0.25	-0.31	-0.31	-0.47	-0.64	-0.49
Diluted Shares Outstanding	18.12M	18.12M	18.22M	18.22M	18.22M	18.27M
Basic Shares Outstanding	18.12M	18.12M	18.22M	18.22M	18.22M	18.27M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	20.6M	16.53M	38.76M	31.72M	21.26M	14.47M
Cash & Short-Term Investments	20.14M	15.47M	37.24M	29.79M	18.78M	12.66M
Cash Only	20.14M	15.47M	37.24M	29.79M	3.69M	4.58M
Short-Term Investments	0	0	0	0	15.08M	8.08M
Accounts Receivable	0	0	1.42M	1.56M	2M	1.45M
Days Sales Outstanding	-	-	-	-	-	-
Inventory	-163.49K	27.67K	76.26K	144.69K	0	0
Days Inventory Outstanding	-	5.71K	5.47K	8.76K	-	-
Other Current Assets	593.08K	1.01M	3.74K	115.86K	64.66K	210.83K
Total Non-Current Assets+	748.68K	967.94K	1.27M	1.72M	1.09M	351.02K
Property, Plant & Equipment	0	18.97K	23.09K	111.64K	57.03K	42.92K
Fixed Asset Turnover	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	88	53.14K	87.8K
Long-Term Investments	0	0	0	0	0	0
Other Non-Current Assets	748.68K	948.97K	1.24M	1.6M	980.71K	220.29K
Total Assets+	21.35M	17.5M	40.03M	33.44M	22.35M	14.82M
Asset Turnover	-	-	-	-	-	-
Asset Growth %	-	-0.18%	1.29%	-0.16%	-0.33%	-0.34%
Total Current Liabilities+	2.49M	2.33M	1.14M	2.18M	1.74M	2.1M
Accounts Payable	572.44K	555.01K	189.87K	1.19M	294.98K	317.83K
Days Payables Outstanding	-	114.45K	13.63K	72.29K	2.59K	-
Short-Term Debt	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	48K	53.24K	100.72K	297.88K	255.06K	324.36K
Current Ratio	8.29x	7.09x	34.15x	14.53x	12.25x	6.89x
Quick Ratio	8.35x	7.07x	34.08x	14.46x	12.25x	6.89x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	11.33K	17.39K	30.62K	116.18K	179.25K	228.93K
Long-Term Debt	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	1.2K
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	11.33K	17.39K	30.62K	116.18K	179.25K	227.72K
Total Liabilities	2.5M	2.35M	1.17M	2.3M	1.91M	2.33M
Total Debt+	0	0	0	0	0	14.6K
Net Debt	-20.14M	-15.47M	-37.24M	-29.79M	-3.69M	-4.57M
Debt / Equity	-	-	-	-	-	0.00x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-484.14x	-720.95x	-485.43x	-	-	-
Total Equity+	18.85M	15.15M	38.86M	31.14M	20.43M	12.5M
Equity Growth %	-	-0.2%	1.56%	-0.2%	-0.34%	-0.39%
Book Value per Share	1.04	0.84	2.13	1.71	1.12	0.68
Total Shareholders' Equity	18.85M	15.15M	38.86M	31.14M	20.43M	12.5M
Common Stock	36.05K	37.06K	65.88M	66.6M	67.34M	68.46M
Retained Earnings	-15.9M	-21.49M	-27.02M	-35.47M	-47.14M	-56.06M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	231.14K	88.95K
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-2.49M	-6.04M	-6.96M	-7.42M	-11.21M	-6.24M
Operating CF Margin %	-	-	-	-	-	-
Operating CF Growth %	-	-1.43%	-0.15%	-0.07%	-0.51%	0.44%
Net Income	-4.6M	-5.59M	-5.53M	-8.48M	-11.65M	-8.91M
Depreciation & Amortization	0	1.9K	4.89K	6.14K	42.45K	44.52K
Stock-Based Compensation	749.51K	460.19K	497.1K	722.74K	739.88K	847.25K
Deferred Taxes	0	0	0	0	0	0
Other Non-Cash Items	4.87K	6.06K	13.23K	90.36K	75.69K	63.11K
Working Capital Changes	1.35M	-920.72K	-1.94M	240.3K	-417.6K	1.72M
Change in Receivables	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	-27.58K	-17.43K	-365.15K	1M	-728.18K	32.08K
Cash from Investing+	0	-20.87K	-9.01K	-27.07K	-14.89M	6.88M
Capital Expenditures	0	-20.87K	-9.01K	-27.07K	-13.79K	-4.47K
CapEx % of Revenue	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	0	-304.99K	0
Cash from Financing+	14.77M	1.39M	28.74M	0	531	270.88K
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	-318.51K	-111.12K	543	0	0	270.88K
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-2.49M	-6.07M	-6.97M	-7.45M	-11.22M	-6.24M
FCF Margin %	-	-	-	-	-	-
FCF Growth %	-	-1.44%	-0.15%	-0.07%	-0.51%	0.44%
FCF per Share	-0.14	-0.33	-0.38	-0.41	-0.62	-0.34
FCF Conversion (FCF/Net Income)	0.54x	1.08x	1.26x	0.88x	0.96x	0.70x
Interest Paid	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-24.44%	-32.97%	-20.47%	-24.22%	-45.16%	-54.13%
Return on Invested Capital (ROIC)	-	-	-652.67%	-558.84%	-97.32%	-59.37%
Debt / Equity	-	-	-	-	-	0.00x
Interest Coverage	-484.14x	-720.95x	-485.43x	-	-	-
FCF Conversion	0.54x	1.08x	1.26x	0.88x	0.96x	0.70x

Frequently Asked Questions

Growth & Financials

Genenta Science S.p.A. (GNTA) grew revenue by 0.0% over the past year. Growth has been modest.

Genenta Science S.p.A. (GNTA) reported a net loss of $20.5M for fiscal year 2024.

Dividend & Returns

Genenta Science S.p.A. (GNTA) has a return on equity (ROE) of -54.1%. Negative ROE indicates the company is unprofitable.

Genenta Science S.p.A. (GNTA) had negative free cash flow of $13.8M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener